<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1887">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136599</url>
  </required_header>
  <id_info>
    <org_study_id>CD2001</org_study_id>
    <secondary_id>R34AI148056</secondary_id>
    <secondary_id>75D30120C08608</secondary_id>
    <nct_id>NCT05136599</nct_id>
  </id_info>
  <brief_title>Establishing a Controlled Human Infection Model of Bordetella Pertussis</brief_title>
  <official_title>Open-label, Phase 1, Dose-escalation Clinical Trial to Establish a Controlled Human Infection Model by Determining the Optimal and Safe Bordetella Pertussis Dose That Induces Mild Symptomatic Infection and Colonization in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dalhousie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Intravacc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dalhousie University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish a Controlled Human Infection Model of Bordetella pertussis by&#xD;
      determining a reproducible and safe infectious bacterial dose (challenge inoculum) that&#xD;
      achieves colonization and mild symptomatic infection in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center trial to develop a Bordetella pertussis Controlled Human Infection&#xD;
      Model (CHIM) using a two-study approach: the first study is a human infectious dose 70%-90%&#xD;
      (HID70-90) identification study, and the second an HID70-90 dose confirmation study to verify&#xD;
      and confirm that the infectious endpoint has been reached. The infectious endpoint is&#xD;
      positive nasopharyngeal culture(s) and/or polymerase chain reaction(s) (PCR(s)) for B.&#xD;
      pertussis with concurrent or subsequent development of mild pertussis disease symptoms such&#xD;
      as rhinorrhea and cough within the 16-day inpatient period following challenge.&#xD;
&#xD;
      The trial is an open-label, phase 1, dose escalation, self-contained trial; participants will&#xD;
      be allocated to challenge dose groups to receive a single intranasal dose of challenge&#xD;
      inoculum. All participants will receive a 5-day course of azithromycin eradication therapy&#xD;
      either 24-48 hours after they develop symptoms or at the end of the 16-day postchallenge&#xD;
      observation period.&#xD;
&#xD;
      The optimal/target inoculum is one that induces mild symptomatic infection and detection of&#xD;
      B. pertussis in nasopharyngeal cultures in 70%-90% of participants receiving it, to establish&#xD;
      a safe and reproducible pertussis CHIM.&#xD;
&#xD;
      Safety monitoring includes close clinical observation during a 16-21-day inpatient&#xD;
      postchallenge period in the Canadian Center for Vaccinology's Challenge Unit, a Data and&#xD;
      Safety Monitoring Board, and participant Diary Cards.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 17, 2022</start_date>
  <completion_date type="Anticipated">November 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Study 1 is a dose-escalation/de-escalation study in which participants will be allocated consecutively to a challenge dose group (arm) with predetermined dose level based on a decision algorithm. (All potential challenge dose groups are listed below, but not all groups may be required.)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with mild symptoms of early pertussis disease postchallenge</measure>
    <time_frame>Day 0 (challenge day) to Day 16</time_frame>
    <description>Mild, Grade 1, symptoms of pertussis are symptoms that do not interfere with everyday activities. They may include malaise, rhinorrhea, sneezing and/or lacrimation, low-grade fever, or cough.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who demonstrate shedding of Bordetella pertussis postchallenge as determined by positive culture and/or PCR test of nasopharyngeal samples</measure>
    <time_frame>Day 1 to Day 14</time_frame>
    <description>The presence of B. pertussis is detected by positive culture (i.e., presence of any B. pertussis colonies) of nasopharyngeal samples. It is also detected by a positive PCR (polymerase chain reaction) test of nasopharyngeal samples. Both methods are used in this study; a positive result in either culture and/or PCR test demonstrates shedding of B. pertussis.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Pertussis</condition>
  <arm_group>
    <arm_group_label>Study 1 (Dose-identification study), Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Challenge dose of 10^3 cfu B. pertussis in 0.2 mL (0.1 mL per naris)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 1 (Dose-identification study), Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Challenge dose of 5 x 10^3 cfu B. pertussis in 0.2 mL (0.1 mL per naris)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 1 (Dose-identification study), Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Challenge dose of 10^4 cfu B. pertussis in 0.2 mL (0.1 mL per naris)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 1 (Dose-identification study), Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Challenge dose of 5 x 10^4 cfu B. pertussis in 0.2 mL (0.1 mL per naris)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 1 (Dose-identification study), Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Challenge dose of 10^5 cfu B. pertussis in 0.2 mL (0.1 mL per naris)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 1 (Dose-identification study), Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Challenge dose of 5 x 10^5 cfu B. pertussis in 0.2 mL (0.1 mL per naris)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study 1 (Dose-identification study), Dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Challenge dose of 10^6 cfu B. pertussis in 0.2 mL (0.1 mL per naris)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bordetella pertussis D420</intervention_name>
    <description>Intranasal inoculation of Bordetella pertussis D420 in each naris on Day 0 of the study.</description>
    <arm_group_label>Study 1 (Dose-identification study), Dose 1</arm_group_label>
    <arm_group_label>Study 1 (Dose-identification study), Dose 2</arm_group_label>
    <arm_group_label>Study 1 (Dose-identification study), Dose 3</arm_group_label>
    <arm_group_label>Study 1 (Dose-identification study), Dose 4</arm_group_label>
    <arm_group_label>Study 1 (Dose-identification study), Dose 5</arm_group_label>
    <arm_group_label>Study 1 (Dose-identification study), Dose 6</arm_group_label>
    <arm_group_label>Study 1 (Dose-identification study), Dose 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for the study, each participant must satisfy ALL of the following criteria:&#xD;
&#xD;
          1. Age 18-40 years, inclusive.&#xD;
&#xD;
          2. Good general health status, as determined by history and physical examination&#xD;
             conducted no longer than 30 days prior to the challenge.&#xD;
&#xD;
          3. Participants who, in the opinion of the Investigator, can and will comply with the&#xD;
             requirements of the protocol (e.g., complete Diary Cards, return for follow-up&#xD;
             visits).&#xD;
&#xD;
          4. Written informed consent obtained from the participant.&#xD;
&#xD;
          5. If female of child-bearing potential and heterosexually active, has practiced adequate&#xD;
             contraception for 28 days prior to challenge and has a negative pregnancy test on the&#xD;
             day of B. pertussis challenge and has agreed to continue adequate contraception until&#xD;
             60 days after inoculation. Adequate contraception is defined as a contraceptive method&#xD;
             with a failure rate of &lt;1% per year when used consistently and correctly and, when&#xD;
             applicable, in accordance with the product label. Examples include the following:&#xD;
&#xD;
               -  Combined (estrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation: oral, intravaginal, or transdermal&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation:&#xD;
                  oral, injectable, or implantable&#xD;
&#xD;
               -  Intra-uterine device (IUD) with or without hormonal release&#xD;
&#xD;
               -  Vasectomized partner, provided that this is the participant's sole partner and&#xD;
                  that he has received a medical assessment of the surgical success&#xD;
&#xD;
               -  Credible self-reported history of heterosexual abstinence for at least 28 days&#xD;
                  prior to challenge&#xD;
&#xD;
               -  Female partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants with ANY of the following criteria at the time of screening will be excluded:&#xD;
&#xD;
          1. Underlying chronic medical condition requiring ongoing follow-up and monitoring by a&#xD;
             physician (e.g., diabetes, seizure disorder).&#xD;
&#xD;
          2. Underlying cardiac and/or pulmonary disease including hypertension, angina, prior&#xD;
             myocardial infarction, asthma, emphysema, chronic bronchitis, and pulmonary&#xD;
             tuberculosis.&#xD;
&#xD;
          3. QT prolongation on electrocardiogram (EKG).&#xD;
&#xD;
          4. Current cigarette smoker or cigarette smoker within the previous 5 years.&#xD;
&#xD;
          5. Pregnant (known before or established at the time of screening using a urine-based&#xD;
             test) or breastfeeding.&#xD;
&#xD;
          6. Immunocompromised (HIV/AIDS-positive or receiving immunosuppressive therapy involving&#xD;
             steroids).&#xD;
&#xD;
          7. Positive for hepatitis B or C.&#xD;
&#xD;
          8. Vaccinated against pertussis within previous 5 years and/or &gt;7 cumulative doses from&#xD;
             infancy to date of screening.&#xD;
&#xD;
          9. Reported history of laboratory-confirmed pertussis infection.&#xD;
&#xD;
         10. Antibody titer to pertussis toxin &gt;10 EU/mL (2x the lower limit of quantification&#xD;
             (LLOQ)).&#xD;
&#xD;
         11. Nasopharyngeal detection of B. pertussis prior to challenge using culture isolation&#xD;
             and/or PCR detection, or detection of other respiratory infection.&#xD;
&#xD;
         12. Living with young children (&lt;1 year of age) or with any household member not current&#xD;
             in their pertussis immunization. (Note: Household members whose vaccination is not&#xD;
             current will be offered a pertussis-containing vaccine, as recommended and funded by&#xD;
             Nova Scotia Department of Health and Wellness.)&#xD;
&#xD;
         13. Known allergy to macrolides including azithromycin or erythromycin, history of&#xD;
             Clostridium difficile within last 2 months.&#xD;
&#xD;
         14. Taking any antibiotic currently or within the previous 2 weeks.&#xD;
&#xD;
         15. Currently taking terfenadine, astemizole, theophylline, or cimetidine.&#xD;
&#xD;
         16. Recent (within 6 months) nasal or sinus surgery, recent use of intranasal steroids (4&#xD;
             weeks), or diagnosis with nasal polyps.&#xD;
&#xD;
         17. Receipt of any investigational drug within 6 months.&#xD;
&#xD;
         18. Receipt of any authorized (approved or investigational) vaccines within 2 weeks of&#xD;
             study immunization.&#xD;
&#xD;
         19. Receipt of experimental SARS-CoV-2/COVID-19 vaccine(s) at any time prior to or during&#xD;
             the study.&#xD;
&#xD;
         20. Known current or previous laboratory-confirmed SARS-CoV-1 or SARS-CoV-2 infection, as&#xD;
             documented by a positive PCR test from a nasal swab or known positive serology.&#xD;
&#xD;
         21. Head trauma (e.g., fracture of the cribriform plate) within 1 year of screening.&#xD;
&#xD;
         22. Any other finding that the Investigator considers will make the participant unsuitable&#xD;
             for the study or unable to comply with the study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott A. Halperin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Watt</last_name>
    <phone>902-470-7479</phone>
    <email>ying.watt@iwk.nshealth.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Canadian Center for Vaccinology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Watt</last_name>
      <phone>902-470-7479</phone>
      <email>ying.watt@iwk.nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Scott A. Halperin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanne M. Langley, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeannette L. Comeau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shelly A. McNeil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>May ElSherif, MBBS, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://centerforvaccinology.ca</url>
    <description>Canadian Center for Vaccinology home page</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bordetella pertussis</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Whooping cough</keyword>
  <keyword>Controlled human infection model</keyword>
  <keyword>Human challenge</keyword>
  <keyword>Phase 1 clinical trial</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

